Stomach cancer detection kit or device, and detection method
This invention relates to a kit or a device for the detection of stomach cancer and a method for detecting stomach cancer, and provides a kit or a device for the detection of stomach cancer, comprising a nucleic acid(s) capable of specifically binding to a miRNA(s) in a sample from a subject, and a method for detecting stomach cancer, comprising measuring the miRNA(s) in vitro.
1. A method for detecting stomach cancer comprising:
determining an expression level(s) of hsa-miR-4257 in a sample comprising blood, serum, or plasma from a human subject using a kit comprising a nucleic acid(s), as a primer(s) for PCR, or a probe(s) for Northern blot, Southern blot, or in situ hybridization, capable of specifically binding to hsa-miR-4257, wherein the determining comprises the following steps of:
(a) contacting hsa-miR-4257 in the sample or complementary polynucleotide(s) thereof prepared from hsa-miR-4257 with the nucleic acid(s);
(b) measuring an expression level of hsa-miR-4257 by quantitative RT-PCR using the nucleic acid(s) as the primer(s), or Northern blot, Southern blot, or in situ hybridization using the nucleic acids as the probe(s); and
(c) comparing the expression level of hsa-miR-4257 measured in the step (b) with a control expression level of hsa-miR-4257 in a control sample from a healthy subject measured in the same way as in the step (b), wherein a lower expression level of hsa-miR-4257 in the sample comprising blood, serum, or plasma from the subject as compared to the control expression level is detected and is indicative that the subject has stomach cancer, and
treating the subject for stomach cancer or performing a diagnostic procedure on the subject, wherein the treatment comprises surgery, radiotherapy, chemotherapy, or a combination thereof, and wherein the diagnostic procedure comprises gastric X-ray examination, gastroscopy, or imaging of the stomach.
2. A method for detecting stomach cancer comprising:
determining an expression level of hsa-miR-4257 in a sample comprising blood, serum, or plasma from a human subject using a device comprising a nucleic acid(s), as a probe(s), capable of specifically binding to hsa-miR-4257, wherein the determining comprises the following steps:
(a) binding hsa-miR-4257 in the sample or cDNA thereof prepared from hsa-miR-4257 to the nucleic acid(s) to measure an expression level of hsa-miR-4257 by hybridization using the nucleic acid(s); and
(b) comparing the expression level of hsa-miR-4257 measured in the step (a) with a control expression level of hsa-miR-4257 in a control sample from a healthy subject measured in the same way as in the step (a), wherein a lower expression level of hsa-miR-4257 in the sample comprising blood, serum, or plasma from the subject as compared to the control expression level is detected and is indicative that the subject has stomach cancer, and
treating the subject for stomach cancer or performing a diagnostic procedure on the subject, wherein the treatment comprises surgery, radiotherapy, chemotherapy, or a combination thereof, and wherein the diagnostic procedure comprises gastric X-ray examination, gastroscopy, or imaging of the stomach.
3. The method according to claim 1 , wherein step (c) further comprises preparing a discriminant based on a formula.
4. The method according to claim 3 , wherein the discriminant is compared to a threshold.
5. The method according to claim 2 , wherein step (b) further comprises preparing a discriminant based on a formula.
6. The method according to claim 5 , wherein the discriminant is compared to a threshold.